225 related articles for article (PubMed ID: 18163212)
1. Medical consequences of acromegaly: what are the effects of biochemical control?
Colao A; Auriemma RS; Pivonello R; Galdiero M; Lombardi G
Rev Endocr Metab Disord; 2008 Mar; 9(1):21-31. PubMed ID: 18163212
[TBL] [Abstract][Full Text] [Related]
2. Acromegaly: re-thinking the cancer risk.
Loeper S; Ezzat S
Rev Endocr Metab Disord; 2008 Mar; 9(1):41-58. PubMed ID: 18157698
[TBL] [Abstract][Full Text] [Related]
3. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.
Colao A; Ferone D; Marzullo P; Lombardi G
Endocr Rev; 2004 Feb; 25(1):102-52. PubMed ID: 14769829
[TBL] [Abstract][Full Text] [Related]
4. Does acromegaly enhance mortality?
Ayuk J; Sheppard MC
Rev Endocr Metab Disord; 2008 Mar; 9(1):33-9. PubMed ID: 18075787
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
6. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
7. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
8. Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment.
García-Álvarez M; Climent V
Minerva Endocrinol; 2019 Jun; 44(2):159-168. PubMed ID: 30482010
[TBL] [Abstract][Full Text] [Related]
9. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly.
Lombardi G; Colao A; Marzullo P; Ferone D; Longobardi S; Esposito V; Merola B
J Endocrinol; 1997 Oct; 155 Suppl 1():S33-7; discussion S39. PubMed ID: 9389993
[TBL] [Abstract][Full Text] [Related]
10. Excess mortality in acromegaly.
Holdaway IM
Horm Res; 2007; 68 Suppl 5():166-72. PubMed ID: 18174739
[TBL] [Abstract][Full Text] [Related]
11. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
12. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
14. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
Fredstorp L; Werner S
J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
[TBL] [Abstract][Full Text] [Related]
16. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.
Ramos-Leví AM; Marazuela M
Endocrine; 2017 Feb; 55(2):346-359. PubMed ID: 28042644
[TBL] [Abstract][Full Text] [Related]
18. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.
Pivonello R; Auriemma RS; Grasso LF; Pivonello C; Simeoli C; Patalano R; Galdiero M; Colao A
Pituitary; 2017 Feb; 20(1):46-62. PubMed ID: 28224405
[TBL] [Abstract][Full Text] [Related]
19. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
